Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial
- PMID: 26067687
- DOI: 10.1016/S1470-2045(15)00027-3
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial
Abstract
Background: In preclinical work and retrospective population studies, the anti-diabetic drug metformin has been associated with antineoplastic activity and decreased burden of many cancers, including pancreatic cancer. There is therefore interest in the hypothesis that this drug might be repurposed for indications in oncology. We aimed to assess the efficacy of the addition of metformin to a standard systemic therapy in patients with advanced pancreatic cancer, and provide the first report of a clinical trial with a survival endpoint of metformin for an oncological indication.
Methods: We did this double-blind, randomised, placebo-controlled phase 2 trial at four centres in the Netherlands. Patients aged 18 years or older with advanced pancreatic cancer were randomly assigned (1:1), via a permutated computer-generated block allocation scheme (block size of six) to receive intravenous gemcitabine (1000 mg/m(2)) on days 1, 8, and 15 every 4 weeks and oral erlotinib (100mg) once daily in combination with either oral metformin or placebo twice daily. Metformin dose was escalated from 500 mg (in the first week) to 1000 mg twice daily in the second week. Randomisation was stratified by hospital, diabetes status, and tumour stage. The primary endpoint was overall survival at 6 months in the intention-to-treat population. This trial is complete and is registered with ClinicalTrials.gov, number NCT01210911.
Findings: Between May 31, 2010, and Jan 3, 2014, we randomly assigned 121 patients to receive gemcitabine and erlotinib with either placebo (n=61) or metformin (n=60). Overall survival at 6 months was 63·9% (95% CI 51·9-75·9) in the placebo group and 56·7% (44·1-69·2) in the metformin group (p=0·41). There was no difference in overall survival between groups (median 7·6 months [95% CI 6·1-9·1] vs 6·8 months [95% CI 5·1-8·5] in the metformin group; hazard ratio [HR] 1·056 [95% CI 0·72-1·55]; log-rank p=0·78). The most frequent grade 3-4 toxic effects were neutropenia (15 [25%] patients in placebo group vs 15 [25%] in metformin group), skin rash (six [10%] vs four [7%]), diarrhoea (three [5%] vs six [10%]), and fatigue (two [3%] vs six [10%]).
Interpretation: Addition of a conventional anti-diabetic dose of metformin does not improve outcome in patients with advanced pancreatic cancer treated with gemcitabine and erlotinib. Future research should include studies of more potent biguanides, and should focus on patients with hyperinsulinaemia and patients with tumours showing markers of sensitivity to energetic stress, such as loss of function of AMP kinase, a key regulator of cellular energy homoeostasis.
Funding: Academic Medical Centre, Amsterdam, and The Terry Fox Foundation, Vancouver, Canada.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Comment in
-
Metformin for pancreatic cancer.Lancet Oncol. 2015 Jul;16(7):748-9. doi: 10.1016/S1470-2045(15)00029-7. Epub 2015 Jun 8. Lancet Oncol. 2015. PMID: 26067686 No abstract available.
Similar articles
-
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.Lancet Oncol. 2017 Apr;18(4):486-499. doi: 10.1016/S1470-2045(17)30084-0. Epub 2017 Mar 2. Lancet Oncol. 2017. PMID: 28259610 Clinical Trial.
-
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.Lancet Oncol. 2016 Feb;17(2):212-223. doi: 10.1016/S1470-2045(15)00483-0. Epub 2015 Dec 23. Lancet Oncol. 2016. PMID: 26727163 Clinical Trial.
-
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.Lancet Oncol. 2013 Jul;14(8):777-86. doi: 10.1016/S1470-2045(13)70254-7. Epub 2013 Jun 17. Lancet Oncol. 2013. PMID: 23782814 Clinical Trial.
-
Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.PLoS One. 2013;8(3):e57528. doi: 10.1371/journal.pone.0057528. Epub 2013 Mar 5. PLoS One. 2013. PMID: 23472089 Free PMC article. Review.
-
Novel advances in pancreatic cancer treatment.Expert Rev Anticancer Ther. 2008 Jun;8(6):993-1002. doi: 10.1586/14737140.8.6.993. Expert Rev Anticancer Ther. 2008. PMID: 18533808 Review.
Cited by
-
Metformin: A Dual-Role Player in Cancer Treatment and Prevention.Int J Mol Sci. 2024 Apr 6;25(7):4083. doi: 10.3390/ijms25074083. Int J Mol Sci. 2024. PMID: 38612893 Free PMC article. Review.
-
Cardiovascular/anti-inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta-analysis of randomized trials.Cancer Med. 2024 Mar;13(5):e7049. doi: 10.1002/cam4.7049. Cancer Med. 2024. PMID: 38491813 Free PMC article.
-
Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Targeted Therapeutic Approaches for the Deadliest Cancer.Int J Mol Sci. 2024 Mar 1;25(5):2860. doi: 10.3390/ijms25052860. Int J Mol Sci. 2024. PMID: 38474109 Free PMC article. Review.
-
Beneficial Effect of Metformin on the Five-Year Survival in about 40,000 Patients with Head and Neck Cancer.Cancers (Basel). 2024 Feb 28;16(5):982. doi: 10.3390/cancers16050982. Cancers (Basel). 2024. PMID: 38473343 Free PMC article.
-
Cancer biology in diabetes update: Focusing on antidiabetic drugs.J Diabetes Investig. 2024 May;15(5):525-540. doi: 10.1111/jdi.14152. Epub 2024 Mar 8. J Diabetes Investig. 2024. PMID: 38456597 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical